Axa
CTIC

Axa’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Axa’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,100
Closed -$103K – 1213
2022
Q4 		$103K Sell
17,100
-16,000
-48% -$87.3K ﹤0.01% 1112
2022
Q3 		$193K Buy
33,100
+17,100
+107% +$107K ﹤0.01% 1096
2022
Q2 		$95.5K Buy
+16,000
New +$81.9K ﹤0.01% 1098
2019
Q1 		– Sell
-27,400
Closed -$20K – 1442
2018
Q4 		$20K Sell
27,400
-34,600
-56% -$56.8K ﹤0.01% 1292
2018
Q3 		$134K Sell
62,000
-43,500
-41% -$108K ﹤0.01% 1313
2018
Q2 		$525K Buy
105,500
+87,000
+470% +$381K ﹤0.01% 1122
2018
Q1 		$72K Buy
+18,500
New +$65.1K ﹤0.01% 1356

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return